1031-37-4 Usage
Uses
Used in Pharmaceutical Industry:
1-benzyl-4-(propylamino)piperidine-4-carboxamide is used as a therapeutic agent for the treatment of neurological and psychiatric disorders such as anxiety, depression, and schizophrenia. Its application is based on its ability to act as a positive allosteric modulator of the mGlu5 receptor, which helps regulate glutamatergic neurotransmission and potentially alleviate symptoms associated with these conditions.
Used in Drug Development Research:
1-benzyl-4-(propylamino)piperidine-4-carboxamide is used as a research compound for studying the role of mGlu5 receptor modulation in the pathophysiology of neurological and psychiatric disorders. Its favorable pharmacokinetic properties and minimal side effects in animal studies make it a valuable tool for further investigation into its potential as a therapeutic agent for these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1031-37-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,3 and 1 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1031-37:
(6*1)+(5*0)+(4*3)+(3*1)+(2*3)+(1*7)=34
34 % 10 = 4
So 1031-37-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H25N3O/c1-2-10-18-16(15(17)20)8-11-19(12-9-16)13-14-6-4-3-5-7-14/h3-7,18H,2,8-13H2,1H3,(H2,17,20)
1031-37-4Relevant academic research and scientific papers
Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system
Mavunkel, Babu J.,Lu, Zhijian,Goehring, R. Richard,Lu, Songfeng,Chakravarty, Sarvajit,Perumattam, John,Novotny, Elizabeth A.,Connolly, Maureen,Valentine, Heather,Kyle, Donald J.
, p. 3169 - 3173 (2007/10/03)
A series of pseudopeptides containing alkyl-, cycloalkyl-, aryl-, and aralkyl-substituted 1,3,8-triazaspiro[4.5]decan-4-one-3-acetic acids as amino acid surrogates to replace the Pro2-Pro3-Gly4-Phe5 section of the peptide bradykinin B2 receptor antagonist [Pro3, Phe5]HOE 140 (D-Arg0-Arg1- Pro2-Pro3-Gly4-Phe5-Ser6-D-Tic7-Oic8-Arg9) were prepared. These psuedopeptides were examined in vitro for their B2 receptor affinities as well as for their ability to block bradykinin mediated actions in vivo. Two compounds in particular, NPC 18521 (I) and NPC 18688 (V) were quite potent in these latter assays, indicating that a significant portion of this prototypical second generation decapeptide antagonist can be replaced with a more compact nonpeptide molecule.
